

FORM 7**MONTHLY PROGRESS REPORT**Name of Listed Issuer: Stillcanna Inc. (the "Issuer").Trading Symbol: STILNumber of Outstanding Listed Securities: 110,874,727Date: April 30, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company announced April 17, 2020 that it signed a comprehensive Letter of Intent to acquire Sativa Group PLC, one of the United Kingdom's first medical Cannabis Companies. The Proposed Transaction, which is arm's-length, will constitute a "Fundamental Change" of the Company under the policies of the Canadian Securities Exchange. The combined assets and licenses of these two

Companies will result in a diverse Company that addresses the majority of sectors within the Cannabis space.

The Company's commitment to Novel Food licensing, and GMP licensing will assure the entities products will be available in markets beyond the February 2021 Novel Food deadline. With extraction and cultivation of all cannabinoids, from wellness to medical research combined with established brands, existing wholesale and retail sales channels, backed by a state-of-the-art laboratory, the new corporate entity will blanket opportunities within the new wellness space.

2. Provide a general overview and discussion of the activities of management.

The Company has implemented multiple cash conservation initiatives in order to maximize savings in light of the recent economic downturn caused by the COVID 19 pandemic along with the drastic market swing experienced in our sector.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to Report

8. Describe the acquisition of new customers or loss of customers.

None to Report

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Company announced that its subsidiary, Borganic Consulting Inc, has secured all licenses and permits required for its ORIGIN extraction facility in Romania to commence the manufacturing of CBD. The facility was constructed through a joint venture partnership with Dragonfly Biosciences Limited of the UK.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None to report

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Company announced that in order to secure the future of the ORIGIN extraction facility and its investment, its subsidiary, Borganic Consulting Inc. has initiated legal action in the UK against Dragonfly Biosciences for contractual breaches under the partnership agreement and the Company is confident that Borganic Consulting will be able to resolve these issues in a timely manner. The Company and its subsidiary Borganic Consulting will continue towards the commencement of manufacturing CBD at the ORIGIN facility as soon as possible.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

13. Provide details of any securities issued and options or warrants granted.

None to report

14. Provide details of any loans to or by Related Persons.

None to report

15. Provide details of any changes in directors, officers or committee members.

None to Report

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company, although still in a strong treasury position has implemented cost-saving measures during this unsettled global environment due to the COVID 19 pandemic.

In January 2019, the European Commission updated the Novel Food Catalogue to state that extracts of Cannabis sativa L. and derived products containing cannabinoids are considered as novel foods, as a history of consumption has not

been demonstrated. As a result, all extracts of hemp and derived products containing cannabinoids (including CBD) are now regarded by the European Commission as novel.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 27, 2020.

Joel Leonard
Name of Director or Senior Officer

DocuSigned by:
Joel Leonard
F2BC76A4ECFA419...
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer Stillcanna Inc.	For End April 2020	Month Date of Report 27/05/20
Issuer Address 503-905 Pender St. W		
City/Province/Postal Code Vancouver/BC/V6C1L6	Issuer Fax No. ()	Issuer Telephone No. ()
Contact Name Joel Leonard	Contact Position CFO	Contact Telephone No. 604-239-0840
Contact Email Address joel@stillcanna.com	Web Site Address www.stillcanna.com	